SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: I. Luttichuys who wrote (625)4/10/1997 11:08:00 PM
From: Miljenko Zuanic   of 1762
 
Bennett,

Thanks for advice. I was IDPH shareholder and I know their research and clinicals. Several thing turned me out. Currently, I am evaluating CE9.1 for RA.
I didn't question validity of Brad info, only asked for source.
It is unusual for pharma to quickly sell biotech holding, which may nothing to have with RA clinical trials. Reasons can be many, who knows.
Because I have small experience in pharmaceuticals plant processes/production, Brad (IDEC) posts regards the CE9.1 manufacturing plants was strange. I will tried to clear this with SmithKline.

Brad, Thanks for reply. For sure that SmithKline finance Analyst can chose many deferent way for projects financing. They are paid for that. Also, reasons for another plant can be many, large demand as wrote , and I expressed "MY LOGIC", as opinion not speculation, regards finance and reason for separate second plant. I do not have info to speculate on this matter.

mz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News